GSK3B and Familial prostate cancer: In addition, targeting GSK3β alone or together with PIM1 has a similar outcome (Fig. S4), suggesting a central role of GSK3β inhibition in regulating peroxisomal biogenesis and LD accumulation in prostate cancer (Figs. 3C−H, S4).